Categories
Latest Industry Intelligence
Download this new whitepaper from Sartorius to understand the unique benefits of the high-throughput iQue [...]
A new eBook is now available for download. This latest eBook sponsored by Bethyl Laboratories/Fortis [...]
The primary endpoint has been achieved in a Phase II trial of AP30663, a first-in-class SK ion channel inhibitor for conversion of atrial fibrillation (AF) to normal sinus rhythm. Acesion Pharma enrolled 63 patients with a current episode of AF in the trial and tested two intravenous doses of AP30663, 3 and 5mg/kg, compared to […]
Menu ≡ ╳ 
